Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years old~* tumor potentially resectable en bloc; tumors tethered or fixed to a structure that can be removed~* clinical/radiological stages T2,T3,or T4, N0-1~* ANC \>1500, PLT\>100,000~* AST and alkaline phosphatase \< 2.5 X ULN~* bilirubin \< 1.5 X ULN~* CrCl \> 50 ml/min using Cockcroft-Gault formula~* KPS \>60~* ECOG Performance Scale 0-2~* No malignancies within previous 5 years other than non-melanoma skin cancer, in-situ cervical cancer, in-situ ductal breast cancer~* no evidence of metastatic disease~Exclusion Criteria:~* initial tumor fixation to pelvic bone or side wide; technically unresectable disease~* any evidence of distant metastasis~* perforation~* obstruction~* hereditary non-polyposis colorectal cancer~* synchronous primary colon carcinomas except T1 lesions~* known dihydropyrimidine dehydrogenase deficiency~* prior radiation therapy to the pelvis~* prior chemotherapy for malignancies~* known existing uncontrolled coagulopathy~* pregnancy or lactation~* women of childbearing potential not using reliable and appropriate contraceptive method~* serious, uncontrolled concurrent infection(s)~* participation in any investigational drug study within 4 weeks preceding the start of study treatment~* clinically significant heart disease~* other serious uncontrolled medical conditions that might compromise study participation (in the investigator's opinion)~* major surgery within 4 weeks prior to the study treatment~* lack of physical integrity of the upper GI tract or malabsorption syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5FU/Leucovorin- post distal rectal srgy (Type: OTHER): Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).